Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica.
Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids.
The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been used to “effectively and safely treat oncological and non-oncological skin conditions.”
“Following our new partnership with Cellmark, the opening of our Tel Aviv office earlier this year, as well as Sensus’ SRT-100 keloid treatment launch in China and market clearance in Mexico in late 2017, the Company’s international efforts are moving full steam ahead in 2018, and our executive team is shifting to meet this growing demand for SRT. Not only are we reaching new patients in these markets who want a less-invasive way to treat non-melanoma skin cancer and keloids without surgery for a better quality of life, we’re also continuing to build relationships with innovative minds in several booming aesthetic markets, due to the recent launch of our new Sensus Laser Systems. This is the time to watch Sensus, as we are uniquely positioned to offer a range of solutions to patients so that they look and feel their best from head to toe,” Sensus CEO Joe Sardano said in a prepared statement.
Sensus said that its oncology and international sales exec VP Rick Golin will spearhead the expansion.
“The market potential for non-invasive solutions for both oncology and aesthetics is vast—hardly a day goes by that we don’t hear from a patient who is seeking out our treatments for his or her skin. Given the simultaneous growth of Sensus’ geographic footprint and product offerings, we’re in a perfect position to meet this demand. We anticipate bringing Sensus’ state-of-the-art, innovative SRT treatments to new territories and countries in the months and years to come, ultimately reaching more patients who are in need all over the world,” Golin said in a press release.
In June 2016, Sensus Healthcare closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each.
